You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

Version: 2 ID: GL #4-4v2 Sep 2020
Type of Content: Guidelines & Advice
Document Status: Current
Authors:
M. Jacobson, N. Coakley , M. Bernardini , L. Elit, S.E. Ferguson, R. Kim, The Gynecologic Guideline Development Group

Guideline Objective

To make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2.

Patient Population

These recommendations apply to women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2.

Intended Guideline Users

This guideline is targeted for: clinicians involved in the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2.

Research Questions

  1. In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 and are at increased risk for epithelial ovarian, fallopian tube, or primary peritoneal cancer, does screening with either serial U/S, CA125 or ROCA, decrease their risk of ovarian cancer?
  2. In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 and are at increased risk for epithelial ovarian, fallopian tube, or primary peritoneal cancer, what is the optimal strategy to prevent these cancers?
  3. What is the optimal post-surgical management protocol to address the sequelae of RRSO in women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2?
pdf download Summary (PDF) (149.41 KB)
pdf download Full Report (PDF) (807.35 KB)